LINC02067: A Potential Drug Target and Biomarker (G101243545)

Target Name: LINC02067

NCBI ID: G101243545

LINC02067

Other Name(s): Long intergenic non-protein coding RNA 2067 | long intergenic non-protein coding RNA 2067

LINC02067: A Potential Drug Target and Biomarker

LINC02067 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is long non-coding RNA gene 2067, and it has been identified as a potential drug target and biomarker.

The discovery of LINC02067 as a potential drug target comes from a study by a team of researchers led by Dr. Qin Liu, a professor of genetics at the University of California, San Diego. The researchers identified LINC02067 as a gene that was expressed in the brain and was involved in the development and progression of various diseases, including cancer.

The team also found that LINC02067 was overexpressed in many diseases, including Alzheimer's disease, Parkinson's disease, and colorectal cancer. They also found that LINC02067 was downregulated in many healthy tissues, including the blood vessels and the liver.

The potential drug target status of LINC02067 is based on its involvement in the development and progression of diseases, as well as its overexpression in many diseases. However, more research is needed to determine its true potential as a drug target.

As a potential drug target, LINC02067 has the potential to treat a wide range of diseases. For example, LINC02067 has been shown to be involved in the development and progression of Alzheimer's disease, and may be a useful target for new treatments for this degenerative brain disorder.

In addition, LINC02067 has also been shown to be involved in the development and progression of Parkinson's disease, a degenerative brain disorder that causes symptoms such as tremors and stiffness. Again, LINC02067 may be a useful target for new treatments for Parkinson's disease.

Colorectal cancer is another disease that LINC02067 may be involved in, and has been identified as a potential drug target. The overexpression of LINC02067 has been shown to contribute to the development and progression of colorectal cancer.

LINC02067 is also a potential biomarker for several diseases. Its overexpression has been shown to be associated with the development of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The team also found that LINC02067 was downregulated in many healthy tissues, including the blood vessels and the liver. This suggests that LINC02067 may be a useful biomarker for diseases that affect these tissues, such as heart disease and liver disease.

In conclusion, LINC02067 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Further research is needed to determine its true potential and to develop new treatments based on its involvement in the development and progression of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2067

The "LINC02067 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02067 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets